Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Factors contributing to the ramifications of this disease as it stands include the socio-economic: overweight and obesity ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Pharmacies will no longer be able to prescribe the drugs following email chats, questionnaires or by people sending in photos ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Pharmacy regulator warns some people with history of eating disorders wrongly obtaining medicines such as Wegovy or Mounjaro ...

Online pharmacies will need a proper consultation, not just a patient's questionnaire, to prescribe jabs such as Mounjaro ...

Previously, the drugs were able to be prescribed through an email chat, from questionnaires or by people sending in photos of ...